These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20393640)

  • 1. Efficacy and safety of biologicals against immune-mediated diseases: do benefits outweigh risks?
    Korkina L; Trakhtman P; De Luca C; Leoni L; Raskovic D; Pastore S
    Drugs Today (Barc); 2010 Feb; 46(2):119-36. PubMed ID: 20393640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The multidisciplinary practice guideline "The responsible use of biologicals"].
    Bijlsma JW; Hagemeijer JW; Bijl M; Jansen TL; van de Laar MA; Landewé RB; Nurmohamed MT
    Ned Tijdschr Geneeskd; 2011; 155(30-31):A3114. PubMed ID: 22085508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Off-label use of biologics for rare immunological disorders].
    Musters A; Assaf A; Baeten DL; Tas SW
    Ned Tijdschr Geneeskd; 2013; 157(49):A6419. PubMed ID: 24299626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New biologics for psoriasis and psoriatic arthritis.
    Rozenblit M; Lebwohl M
    Dermatol Ther; 2009; 22(1):56-60. PubMed ID: 19222517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic response modifiers: Indications, implications, and insights.
    Davis BP; Ballas ZK
    J Allergy Clin Immunol; 2017 May; 139(5):1445-1456. PubMed ID: 28263774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety.
    Xu Z; Davis HM; Zhou H
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S60-74. PubMed ID: 25707965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic therapies for psoriasis: understanding current and newly emerging therapies.
    Sobell JM; Hallas SJ
    Semin Cutan Med Surg; 2003 Sep; 22(3):187-95. PubMed ID: 14649586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions.
    Frieder J; Kivelevitch D; Haugh I; Watson I; Menter A
    Clin Pharmacol Ther; 2018 Jan; 103(1):88-101. PubMed ID: 28960267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New drugs and treatment targets in psoriasis.
    Kofoed K; Skov L; Zachariae C
    Acta Derm Venereol; 2015 Feb; 95(2):133-9. PubMed ID: 25111317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hazard identification and risk assessment for biologics targeting the immune system.
    Weir AB
    J Immunotoxicol; 2008 Jan; 5(1):3-10. PubMed ID: 18382852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing human biologicals in animal host resistance models.
    Burleson GR; Burleson FG
    J Immunotoxicol; 2008 Jan; 5(1):23-31. PubMed ID: 18382855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies.
    Carrascosa JM; van Doorn MB; Lahfa M; Nestle FO; Jullien D; Prinz JC
    J Eur Acad Dermatol Venereol; 2014 Nov; 28(11):1424-30. PubMed ID: 24841895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of biologic agents in pediatric psoriasis.
    Marji JS; Marcus R; Moennich J; Mackay-Wiggan J
    J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunologic Adverse Effects of Biologics for the Treatment of Atopy.
    Aranez V; Ambrus J
    Clin Rev Allergy Immunol; 2020 Oct; 59(2):220-230. PubMed ID: 31301006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
    Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
    J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics.
    Levine D; Strober BE
    Semin Cutan Med Surg; 2010 Mar; 29(1):28-34. PubMed ID: 20430305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining traditional systemic and biologic therapies for psoriasis.
    Heffernan MP
    Semin Cutan Med Surg; 2010 Mar; 29(1):67-9. PubMed ID: 20430311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologics for the treatment of autoimmune renal diseases.
    Holdsworth SR; Gan PY; Kitching AR
    Nat Rev Nephrol; 2016 Apr; 12(4):217-31. PubMed ID: 26949177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous side-effects of biologics in immune-mediated disorders: A histopathological perspective.
    Succaria F; Bhawan J
    J Dermatol; 2017 Mar; 44(3):243-250. PubMed ID: 28256759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.